Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy – a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib.

Trial Profile

Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy – a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top